Recent studies have demonstrated the existence of a novel family of calcium-independent plasmalogen-selective phospholipases A2 in canine myocardium that have been implicated as enzymic mediators of ischemic membrane damage. We now report that human myocardium contains two functionally distinct isoforms of cytosolic calcium-independent phospholipase A2. The major cytosolic phospholipase A2 isoform preferentially hydrolyzes plasmalogen substrate, possesses a pH optimum of 7.0, and is chromatographically resolvable from a minor cytosolic calcium-independent phospholipase A2 isoform that hydrolyzes plasmenylcholine and phosphatidylcholine substrates at similar rates and possesses a pH optimum of 8.5. The major cytosolic calcium-independent phospholipase A2 isoform was identified as a 40-kD polypeptide after its 182,000-fold purification by sequential column chromatographies to a final specific activity of 67 mumol/mg.min. The purified 40-kD human myocardial phospholipase A2 preferentially hydrolyzes plasmalogens containing arachidonic acid at the sn-2 position. Both reverse-phase HPLC and fast atom bombardment mass spectroscopic analysis of human myocardial ethanolamine and choline glycerophospholipids demonstrated that plasmenylethanolamine and plasmenylcholine molecular species containing arachidonic acid at the sn-2 position are prominent constituents of human myocardium. Collectively, these results identify and characterize the major human myocardial cytosolic calcium-independent phospholipase A2 
Introduction
Phospholipases are critical proximal enzymic mediators ofsignal transduction processes in mammalian cells because they catalyze the regiospecific cleavage ofthe chemical precursors of biologically active lipid-derived second messengers (cf. references [1] [2] [3] [4] . The highly regulated and specific activation of intracellular phospholipases facilitates the appropriate adaptation of cellular function to external perturbations. However, the inappropriate activation of these signal transducers has been recognized as an important biochemical mechanism contributing to the pathophysiologic sequelae of several disease states including inflammation, atherosclerosis, and ischemic membrane dysfunction (cf. references [5] [6] [7] [8] [9] . In myocardium, accelerated phospholipid catabolism resulting from the activation ofphospholipases A2 during ischemia has been implicated as the biochemical mechanism precipitating electrophysiologic dysfunction and myocytic cellular necrosis during myocardial infarction (e.g., references [10] [11] [12] [13] [14] [15] . Accordingly, recent attention has focused on the identification and characterization of enzymes mediating phospholipid catabolism in myocardium from a wide variety of mammalian species and the elucidation ofthe molecular identities ofindividual phospholipid constituents that serve as their substrates during an ischemic insult. Although substantial insights into some ofthe characteristics of enzymes mediating phospholipid catabolism in several species of mammalian myocardium have been made ( 13, (16) (17) (18) (19) (20) (21) , little information is presently available on the detailed chemical characteristics of human myocardial phospholipase(s) A2, the multiplicity of different phospholipases A2 present in human myocardium or the chemical identities of the individual phospholipid constituents present in human myocardium which serve as their lipid substrates.
Prior studies ofthe individual molecular species ofphospholipids present in mammalian myocardium obtained from several species demonstrated the unanticipated finding that some subcellular membranes (e.g., sarcolemma and sarcoplasmic reticulum) were predominantly composed ofplasmalogen molecular species containing arachidonic acid at the sn-2 position (22, 23) . The potential physiologic and pathophysiologic significance ofthe high plasmalogen content present in these critical myocardial subcellular membrane compartments was underscored by the identification of a calcium-independent phospholipase A2 in canine myocardium which selectively utilized plasmalogen substrate (17) . It is now well established that myocardial plasmalogen content has substantial interspecies variation (22) (23) (24) (25) (26) (27) , and that a diverse array of phospholipases A2 are present in mammalian tissues ( 13, 16, 17, 18, 20, 21 ) . To delineate the individual molecular species of phospholipids present in human myocardium and to characterize the enzymes mediating their catalysis, human myocardial cytosolic phospholipase A2 was purified from fresh human myocardium obtained from transplant recipients and detailed analyses of individual human myocardial phospholipid molecular species were performed. We nowjreport the purification of the major human myocardial cytosolic calcium-independent phospholipase A2 activity to apparent homogeneity, identify the presence of cytosolic calcium-independent phospholipase A2 isoforms with distinct physical and kinetic characteristics, and demonstrate that the major observable cytosolic phospholipase A2 isoform preferentially catalyzes the hydrolysis of plasmenylcholine substrate containing arachidonic acid at the sn-2 position which is an abundant phospholipid constituent of human myocardium.
Methods
Isolation of human myocardial cytosolic calcium-independent phospholipase A2. Human myocardial cytosolic calcium-independent phospholipase A2 was isolated utilizing a modification of the scheme employed for the purification ofcanine cytosolic phospholipase A2 (20, 28 (20) . Briefly, crude myocardial homogenate was initially centrifuged at 10,000 gm,, for 20 min and the upper layer ofthe supernatant containing visible lipid was gently removed by aspiration. The resultant supernatant was then centrifuged at 85,000 gl, for 60 min and the microsomal pellet was discarded.
Human myocardial cytosolic calcium-independent phospholipase A2 was purified by sequential anion exchange, chromatofocusing, ATP-affinity, and Mono-Q chromatographies (20) . Briefly, human myocardial cytosol was filtered through glass wool, dialyzed against 2 X 10 liter (8 h each) of buffer 1 ( 15 mM imidazole, 5 mM K[P04], 10% glycerol, pH 7.8) and loaded onto a preequilibrated DEAE-Sephacel column (5 X 5 cm, 2.5 ml/min). The column was washed with buffer 1 containing 1 mM DTT, and developed with a discontinuous step gradient of 0.2 M NaCl followed by 1 M NaCl in 10 mM imidazole, 10 mM KCl, 10% glycerol, 1 mM DTT, pH 8.0. Fractions containing the majority of phospholipase A2 activity in the 0.2 M NaCl eluent were identified, pooled, and dialyzed against 20 liter of buffer 2 ( 10 mM imidazole, 10 mM KCl, 25% glycerol, 1 mM DTT, pH 8.0) for 15 h. The dialyzed DEAE-Sephacel 0.2 M NaCl eluent was next loaded onto a previously equilibrated PBE-94 (Pharmacia-LKB Biotechnology, Piscataway, NJ) chromatofocusing column (1.6 X 30 cm, 1.5 ml/ min), which was developed with a pH gradient generated by application of buffer composed of 10% PB96, 5% PB74, 25% glycerol, 1 mM DTT, pH 5.4. Fractions containing the majority of phospholipase A2 activity were immediately identified, pooled, and applied to a 1 X 1 cm N6_ [ (6-aminohexyl) carbamoyl-methyl ] ATP-agarose affinity column previously equilibrated in buffer 3 (10 mM imidazole, 25% glycerol, 1 mM DTT, pH 8.3). After loading, the affinity column was washed with buffer 3, buffer 3 containing 10 mM AMP (which removes the majority of bound proteins), buffer 3 alone (to remove UV absorbing AMP) and, finally, buffer 3 containing 1 mM ATP (which eluted human myocardial calcium-independent phospholipase A2 in near quantitative yield). The active fractions from the ATP-agarose affinity column eluent were then applied to an HR5/5 Mono-Q column (Pharmacia-LKB Biotechnology) previously equilibrated in buffer 4 (20 mM imidazole, 25% glycerol, 1 mM DTT, pH 8.3) and phospholipase A2 was eluted utilizing a discontinuous NaCl gradient (0-500 mM).
Preparation of synthetic phospholipids. Homogeneous 16:0,[3HH 18:1 (1.4 X 106 dpm/nmol) and 16:0,[3H]20:4 (6.7 x I05 dpm/ nmol) plasmenylcholine and phosphatidylcholine molecular species were prepared by condensation ofdicyclohexylcarbodiimide-generated 3H-fatty acid anhydride with the appropriate reverse-phase HPLC-purifled lysophospholipid as previously described (29) . Polar head group-labeled plasmenyicholine (2.0 X 105 dpm/nmol) was synthesized similarly utilizing ( ( 31 ) . Each radiolabeled choline glycerophospholipid was initially purified by preparative TLC and subsequently purified by Partisil SCX-HPLC chromatography (P. J. Colbert, Inc., St. Louis, MO) as previously described (20, 29) . To facilitate direct kinetic comparisons between diacyl and vinyl ether subclasses, radiolabeled molecular species of identical specific activities were synthesized utilizing common preparations of freshly synthesized radiolabeled fatty acid anhydride as reagent. The purity and regiospecificity of each radiolabeled synthetic product was confirmed by TLC in two solvent systems, straight-phase HPLC, comigration with authentic standards on reverse-phase HPLC, as well as isolation and quantitation ofreaction products generated by either Naja naja phospholipase A2 or Bacillus cereus phospholipase C catalysis as previously described (20 (32) and subsequently stored at -20°C under a nitrogen atmosphere in chloroform. Human myocardial choline and ethanolamine glycerophospholipids from Bligh and Dyer extracts were purified by straight-phase HPLC employing an Ultrasphere Si column (4.6 x 250 mm; 5 tm particles) and gradient elution with hexane/isopropanol/water (48.5/48.5/3, vol/vol/vol) as the initial mobile phase and hexane/isopropanol/water (46.5/46.5/7, vol/vol/ vol) as the final mobile phase as described previously (33) . Column eluents were evaporated under a nitrogen stream and the purified choline and ethanolamine glycerophospholipids were resuspended and stored at -20°C in 2 ml each of chloroform under a nitrogen atmosphere.
Individual molecular species ofhuman myocardial choline and ethanolamine glycerophospholipids were resolved after preparation of their monobenzoate diradyl glycerol derivatives as previously described (34) . In brief, 1 mg of either straight-phase HPLC-purified human myocardial choline or ethanolamine glycerophospholipids was dried under a nitrogen stream and resuspended in ferrous sulfatewashed diethyl ether before incubation with Bacillus cereus phospholipase C (20 U) for 60 min at 22°C. The resultant diradyl glycerols were directly benzoylated with benzoic anhydride utilizing NN-dimethyl-4-aminopyridine as catalyst (34) . Monobenzoate diradyl glycerol derivatives ofhuman myocardial choline or ethanolamine glycerophospholipids were purified by thin layer chromatography utilizing silica G TLC plates and a mobile phase comprised of hexane/diethyl ether/ammonium hydroxide ( 85/ 15/ 1, vol/vol/vol). Regions of the TLC plate corresponding to the purified monobenzoate diradyl glycerols were scraped into test tubes, extracted with chloroform/methanol ( 1 / 1, vol/ vol), dried under a stream of nitrogen gas and resuspended in 50 z1 of acetonitrile/isopropanol (85/15, vol/vol). Individual monobenzoate diradyl glycerol derivatives of human myocardial choline or ethanolamine glycerophospholipid molecular species were subsequently resolved by reverse-phase HPLC utilizing an octadecyl silica stationary phase and an acetonitrile/isopropanol (85/15, vol/vol) mobile phase at a flow rate of 1 ml/min. Identification of each monobenzoate diradyl glycerol molecular species derived from human myocardial choline or ethanolamine glycerophospholipids was facilitated by collecting column eluents from each UV absorbing peak (231 nm), drying eluents under nitrogen and analyzing their acid methanolysis derivatives by capillary gas chromatography. The relative mass distribution ofindividual molecular species ofstraight-phase HPLC purified human myocardial choline or ethanolamine glycerophospholipids was also independently determined by fast atom bombardment mass spectrometry as previously described (22) .
Sources ofmaterials and miscellaneous procedures. Bolton-Hunter iodination, SDS-PAGE, '25I autoradiography, and protein determinations were performed as previously described (20 
Results
Chromatographic resolution and kinetic characterization ofhuman myocardial cytosolic phospholipase A2 isoforms. To characterize the polypeptide(s) mediating phospholipase A2 activity in human myocardial cytosol, the protein constituents in dialyzed cytosol were initially fractionated by anion exchange chromatography. The majority of phospholipase A2 activity was adsorbed to the stationary phase under the conditions employed and was eluted by application of buffer containing 200 mM NaCl. However, a second peak ofphospholipase A2 activity required higher salt concentrations for elution (peak 2) (Fig. 1 ). Phospholipase A2 activity in peak 1 represented -90% of recovered activity and was relatively stable while the enzymatic activity in peak 2 accounted for -10% of eluted activity and was markedly labile under the conditions employed. No calcium-dependent phospholipase A2 activity in the cytosol or in column eluents was detectable under the conditions employed.
To determine if the polypeptide(s) catalyzing calcium-independent phospholipase A2 activity in peaks 1 and 2 ( Fig. 1) possessed similar physical and kinetic characteristics, the substrate specificities, calcium requirements, and pH profiles of enzymatic activity in each peak were determined. Phospholipase A2 activity in peak 1 was calcium-independent, neutral active (pH optimum 7 (Fig. 2) . Phospholipase A2 activity in peak 2 was also calcium-independent but, in sharp contrast, it possessed a basic pH optimum (pH 8.5) and hydrolyzed phosphatidylcholine and plasmenylcholine substrates at similar rates (Fig. 2) . The regiospecificity of phospholipase A2 activities in peaks 1 and 2 was confirmed Figure 1 . DEAE-Sephacel chromatography of human myocardial cytosolic calcium-independent phospholipases A2. Human myocardial cytosol was dialyzed and loaded onto a DEAE-Sephacel column, and phospholipase A2 activity was eluted with a discontinuous NaCl gradient as described in Methods. Aliquots of column eluents were assayed by quantifying radiolabeled fatty acid released (.) from 16:0, [3H] 18:1 plasmenylcholine as described in Methods. ( ) UV absorbance at 280 nm.
by demonstration of the concomitant release of sn-2 radiolabeled fatty acid and polar head group labeled lysoplasmenylcholine from 16 this fraction in our hands. Phospholipase A2 activity in peak 1 was focused into a major peak eluting at pI 6.9 during chromatofocusing which was reproducibly preceded by a smaller peak ofactivity eluting between pH 7.6-7.7 (Fig. 3) . Further characterization ofthe pH optimum and choline glycerophospholipid subclass selectivity ofthe peak fraction from the major peak (pI 6.9) demonstrated the selective hydrolysis of vinyl ether containing choline glycerophospholipids at a pH optimum of 7.0. Interestingly, the earlier eluting peak preceding the elution of the major position ofphospholipase A2 activity hydrolyzed diacyl and vinyl ether containing choline glycerophospholipids at similar rates and possessed a pH optimum of 9 (similar to the behavior of peak 2 from the DEAE-Sephacel column).
Chromatofocusing fractions possessing the majority of phospholipase A2 activity were pooled and subsequently loaded onto an ATP-agarose affinity matrix as described in Methods. Phospholipase A2 activity selectively and quantitatively adsorbed to the ATP-affinity matrix while the majority of other proteins eluted in the void volume (Fig. 4) . Application of buffer containing 10 mM AMP failed to elute substantive amounts of phospholipase A2 activity even though the large majority of proteins which were adsorbed onto the affinity matrix were eluted (Fig. 4) . Subsequent application of buffer containing 1 mM ATP resulted in recovery of 85% of applied phospholipase A2 activity with a 120-fold purification of human myocardial cytosolic phospholipase A2 activity achieved in a single step (Table I, Fig. 4 ). Human myocardial cytosolic calcium-independent phospholipase A2 was subsequently purified to apparent homogeneity by application ofthe ATP-agarose eluent to an HR5 / 5 Mono-Q column with subsequent elution utilizing a shallow discontinuous NaCl gradient -* 50 * Subsequent purification of cytosolic phospholipase A2 activity utilized peak 1 from DEAE-Sephacel chromatography. § I M NaCI eluent.
( Fig. 5) . Collectively, this series of column chromatographic steps resulted in the 182,000-fold purification of the major human myocardial cytosolic calcium-independent phospholipase A2 isoform in 38% yield to a final specific activity of 67 .mol/ mg min (Table I) .
SDS-PAGE and 125I autoradiography. The purity of the phospholipase A2 preparation was analyzed by SDS-PAGE and 1251 autoradiography after Bolton-Hunter iodination (Fig. 6 ). An intense band at 40 kD was observed in the most active fraction (fraction 13) from Mono-Q chromatography. Furthermore, the intensity ofthe 40-kD band precisely correlated with the relative amounts ofphospholipase A2 activity found in each fraction of Mono-Q column chromatographic eluent. The high 10 FRACTION Figure 5 . Mono-Q chromatography of human myocardial cytosolic calcium-independent phospholipase A2. Active fractions from ATP affinity chromatography were pooled and loaded onto an HR5/5 fast protein liquid chromatography-Mono-Q column, and phospholipase A2 was eluted utilizing a nonlinear NaCl gradient as described in Methods. Phospholipase A2 activity was assessed utilizing sensitivity and dynamic range of the visualization method employed (125I autoradiography), the high specific activity of the purified polypeptide (67 gmol/mg -min), as well as the concordant appearance and disappearance ofthe 40-kD band with phospholipase A2 activity collectively demonstrate that the 40-kD polypeptide catalyzes human myocardial phospholipase A2 activity.
Kinetic characterization of purified human myocardial phospholipaseA2. To determine the phospholipid class selectivity of human myocardial cytosolic calcium-independent phospholipase A2, two types of kinetic experiments were performed. First, the initial velocity of phospholipase A2 activity was determined as a function of substrate concentration utilizing either homogeneous phosphatidylcholine, phosphatidylinositol, or phosphatidylethanolamine containing radiolabeled arachidonic acid at the sn-2 position. Both phosphatidylcholine and phosphatidylinositol are present in the bilayer configuration at the assay temperature employed (i.e., 37°C), while phosphatidylethanolamine assumes an inverted hexagonal II configuration at this temperature ( 35 In that the activities of phospholipases A2 are profoundly influenced by the interfacial characteristics of aggregate substrate, additional experiments were performed to compare hydrolysis ofthese individual classes ofarachidonic acid containing phospholipids presented as substitutional impurities in vesicles comprised of binary mixtures of 10 mol% radiolabeled phosphatidylinositol, phosphatidylcholine, or phosphatidylethanolamine and 90 mol% unlabeled phosphatidylcholine ( 16:0, 20:4). The rank order of substrate class selectivity in this system was phosphatidylcholine > phosphatidylethanolamine > phosphatidylinositol (Table II) . Thus, these results demonstrate that phosphatidylinositol is a suitable substrate for human myocardial phospholipase A2 when presented in a physiologically relevant bilayer system possessing physiologically relevant surface charge and zwitterionic character (i.e., phosphatidylinositol was hydrolyzed at over one-half the rate observed for phosphatidylethanolamine in similar phosphatidylcholine matrices). The change in the relative rank order of substrate class selectivities (i.e., choline vs. ethanolamine glycerophospholipid) demonstrates that the physical state and interfacial characteristics of aggregate substrates are important Released radiolabeled fatty acid was subsequently isolated after butanol extraction, separated by TLC, and quantified by scintillation spectrometry as described in Methods. determinants of the catalytic efficiency of human myocardial calcium-independent phospholipase A2.
To examine the subclass and molecular species specificities of the purified human myocardial phospholipase A2, additional experiments were performed utilizing phosphatidylcholine and plasmenylcholine substrates containing either radiolabeled oleic acid or arachidonic acid at the sn-2 position and enzyme purified through the ATP column chromatographic step (8,600-fold purified). Comparisons of the relative rates of hydrolysis demonstrated that human myocardial phospholipase A2 preferentially hydrolyzed vinyl ether containing choline glycerophospholipids (Fig. 7) . Furthermore, plasmenylcholine substrate containing arachidonic acid at the sn-2 position was hydrolyzed over twofold more rapidly than plasmenylcholine substrate containing oleic acid at the sn-2 position. This contrasted with phosphatidylcholine molecular species containing either oleic or arachidonic acid at the sn-2 position which manifest similar rates of hydrolysis at each substrate concentration examined.
Identification of human myocardial choline and ethanolamine glycerophospholipid molecular species by reverse-phase HPLC and fast atom bombardment mass spectrometry. Because human myocardial phospholipase A2 possesses a selectivity for plasmalogen substrate, the chemical identities ofindividual choline and ethanolamine glycerophospholipid molecular species in human myocardium were determined to document the presence of these substrates. Human myocardial phospholipids were extracted from ventricular tissue by the method of Bligh and Dyer (32) and individual phospholipid classes were purified by straight-phase HPLC as described in Methods. Re- (9), and 18:0-18:1 phosphatidylcholine (10). Assignments of molecular species identities of derivatized ethanolamine and choline glycerophospholipids to each peak were determined by derivatizing eluents corresponding to each peak by acid methanolysis and subsequent analysis by capillary gas chromatography.
verse-phase HPLC of monobenzoate diradyl glycerol derivamolecular species present in human myocardial ethanolamine tives of human myocardial ethanolamine glycerophospholipglycerophospholipids contained stearic acid at the sn-1 posiids, as well as fast atom bombardment mass spectroscopic analtion and arachidonic acid at the sn-2 position (Figs. 8 A and 9 ysis of underivatized ethanolamine glycerophospholipids, A, Table III ). revealed that plasmenylethanolamine is the predominant moReverse-phase HPLC ofmonobenzoate diradyl glycerol delecular subclass of human myocardial ethanolamine glycerorivatives ofhuman choline glycerophospholipids, as well as fast phospholipids (Figs. 8 A and 9 A; Table III Table III ). Plasmenylcholine A; Table III Table III ). These results demonstrate the predominance of plasmalogens in the ethanolamine glycerophospholipid pool and the abundance of vinyl ether linkages in choline glycerophospholipid molecular species in human myocardium.
Discussion
The relationship of accelerated phospholipid catabolism during myocardial ischemia to the pathophysiologic sequelae of myocardial infarction has been an area of extensive investigation during the last decade. A multiplicity ofexperimental animal and cell culture models has been employed to study the potential relevance of the activation of phospholipases to the electrophysiologic dysfunction and myocytic cellular necrosis manifest during human myocardial infarction. During the course of these studies, a large diversity of mammalian phospholipases has been identified and an intriguing heterogeneity of individual phospholipid constituents in myocardium from many different species has been documented. Specifically, in several animal species (e.g., dog and rabbit) plasmalogens are the predominant phospholipid constituent of critical subcellular membranes (e.g., sarcolemma and sarcoplasmic reticulum) (22, 23) , and plasmalogen-selective phospholipases A2 are the major measurable phospholipase activity in many tissues ( 13, 17, 20) . Despite substantial evidence implicating the importance of plasmalogen catabolism during ischemic and reperfusion injury ( 13, 14, (36) (37) (38) , the purification ofhuman myocardial phospholipase A2 and the chemical identification of the individual molecular species of human myocardial phospholipids have not been forthcoming. Herein we demonstrate that the major isoform of human myocardial cytosolic calcium-independent phospholipase A2 activity is a 40-kD polypeptide (similar to that found in other mammalian species such as canine and rabbit myocardium) ( 13, 20) and that plasmenylcholine and plasmenylethanolamine molecular species enriched in arachidonic acid represent prominent chemical constituents of human myocardial phospholipids. The purification strategy for this human myocardial phospholipase A2 exploited the previously identified affinity interaction between cytosolic calcium-independent phospholipase A2 and ATP (39) which facilitated the 182,000-fold purification of the human myocardial enzyme in 38% overall yield. During the course ofthe purification, evidence for the presence of functionally distinct isoforms ofcalcium-independent phospholipase A2 was uncovered. In contrast to previous experimental results in both canine and rabbit myocardium, human myocardium contained a calcium-independent phospholipase A2 activity which required high salt for elution from the anion exchange matrix and possessed distinct physical and kinetic properties. Although the major phospholipase A2 isoform selectively hydrolyzed plasmalogen substrate, possessed a pH optimum of 7.0, and was relatively stable, the minor isoform (eluting at high NaCl concentrations) hydrolyzed plasmenylcholine and phosphatidylcholine substrates at similar rates, possessed a pH optimum of 8.5 and was markedly labile. Although definitive identification of the presence of two separate phospholipase A2 gene products requires sequence determination and detailed chemical analyses of both isoforms, the present results identify the existence of two functionally distinct calcium-independent phospholipase A2 activities in human myocardium. The precise chemical differences underlying these functional alterations remain unknown at present. 2520 Kinetic analyses ofthe class, subclass and molecular species specificities of the purified human myocardial phospholipase A2 in multiple systems demonstrated that plasmalogens containing arachidonic acid at the sn-2 position are the preferred substrates. Accordingly, the molecular species distribution of phospholipids in human myocardium was analyzed by two independent methods to document the presence of plasmalogens and to identify the relative content of individual molecular species containing arachidonic acid. Substantial amounts of plasmenylcholine and plasmenylethanolamine molecular species containing arachidonic acid were identified in human myocardium. These results represent the first identification of the individual molecular species distribution of phospholipids in human myocardium. The abundance ofplasmalogen molecular species in human myocardium resembles that found in canine, rabbit and hamster myocardium and exceeds that present in rat or guinea pig myocardium (22) (23) (24) (25) (26) (27) .
Conclusion. These results represent the first reported isolation ofcalcium-independent phospholipase A2 and its purification to apparent-homogeneity from intact human tissue. They further underscore the potential significance of calcium-independent phospholipases A2 as the enzymic mediators of ischemia-induced phospholipolysis because this class of enzymes constitutes the overwhelming majority of measurable phospholipase activity in human myocardium. Accordingly, human myocardial cytosolic calcium-independent phospholipases A2 represent an attractive target for pharmacologic attenuation of ischemic membrane dysfunction in compromised myocardium. Mechanism-based discrimination between calcium-dependent and calcium-independent phospholipases A2 employing suicide inhibition has recently been reported (40) . The development of isoform-specific calcium-independent phospholipase A2 inhibitors which achieve their selectivity by exploiting the chemical determinants responsible for the distinct substrate specificities exhibited by calcium-independent phospholipase A2 isoforms should facilitate the development of selective agents capable of attenuating membrane dysfunction during myocardial ischemia.
